Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Oral Oncol. 2018 Feb;77:98-104. doi: 10.1016/j.oraloncology.2017.12.013. Epub 2017 Dec 28.
Adenoid cystic carcinoma (AdCC) in the salivary gland shows a high rate of distant metastasis, which is related to the resulting poor prognosis. We therefore examined the role of pretreatment F-FDG PET/CT for prediction of distant metastasis, recurrence/progression, and survival in AdCC.
This study included 52 patients who underwent pretreatment F-FDG PET/CT scanning and subsequent treatments for AdCC. Maximum, mean, and peak standardized uptake value (SUV, SUV, and SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured on F-FDG PET/CT. Univariate and multivariate Cox proportional hazards regression analyses were used to identify associations between the quantitative measurements of F-FDG PET, and progression-free survival (PFS), distant metastasis-free survival (DMFS), and disease-specific survival (DSS).
Distant metastases were found in 20 (39%) patients: 6 (12%) at initial diagnosis and 14 (27%) during the median follow-up of 72 months after treatment. Univariate analyses showed that all the F-FDG PET parameters of SUV, SUV, SUV, MTV, and TLG were significantly associated with overall PFS, DMFS, and OS (all P < .05). After controlling for clinicopathological variables, SUV remained an independent factor predictive of PFS (P = .001), while MTV and TLG were independent predictors of DMFS (P = .009) and DSS (P = .017). Patients with MTV > 14.8 mL showed a 5.9-fold higher risk of distant metastasis and a 4.2-fold higher risk of disease-specific death than those with a lower MTV.
Quantitative measurements using F-FDG PET/CT are useful for predicting tumor progression, distant metastasis, and survival in patients with AdCC.
涎腺腺样囊性癌(AdCC)远处转移率高,导致预后不良。因此,本研究旨在探讨 18F-FDG PET/CT 摄取参数在预测腺样囊性癌远处转移、复发/进展和生存中的作用。
本研究纳入 52 例经 18F-FDG PET/CT 扫描及后续治疗的 AdCC 患者。在 F-FDG PET/CT 上测量最大标准摄取值(SUVmax)、平均标准摄取值(SUVmean)、最大标准摄取值(SUVpeak)、代谢肿瘤体积(MTV)和总肿瘤糖酵解(TLG)。采用单因素和多因素 Cox 比例风险回归分析来确定 F-FDG PET 定量测量值与无进展生存期(PFS)、无远处转移生存期(DMFS)和疾病特异性生存期(DSS)之间的相关性。
20 例(39%)患者发生远处转移:6 例(12%)在初始诊断时,14 例(27%)在治疗后中位 72 个月随访时。单因素分析显示,SUVmax、SUVmean、SUVpeak、MTV 和 TLG 等 F-FDG PET 参数均与总 PFS、DMFS 和 OS 显著相关(均 P<0.05)。在校正临床病理变量后,SUVmax 仍然是 PFS 的独立预测因素(P=0.001),而 MTV 和 TLG 是 DMFS(P=0.009)和 DSS(P=0.017)的独立预测因素。MTV>14.8 mL 的患者远处转移风险增加 5.9 倍,疾病特异性死亡风险增加 4.2 倍。
18F-FDG PET/CT 摄取参数定量测量有助于预测 AdCC 患者的肿瘤进展、远处转移和生存。